RxDoctor Payments Data

Russell Fisher, DO

Cardiovascular Disease · Bedford, TXNPI 1740282268

Payments from drug & device makers

$13,740in general payments, 2019–2025

Across 730 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Novartis$1K
  • Amgen$1K
  • AstraZeneca$923
  • Merck$747
  • Amarin Pharma, Inc.$706
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$13,36997%
  • Education$3723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,740 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$384,916
Medicare patients
406
Services billed
3,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban690$698,942
ArcalystRilonacept12$380,633
EntrestoSacubitril/Valsartan218$244,244
XareltoRivaroxaban142$132,178
Repatha SureclickEvolocumab109$94,740
FarxigaDapagliflozin Propanediol63$55,445
MultaqDronedarone Hcl37$48,005
VascepaIcosapent Ethyl77$38,322
JardianceEmpagliflozin30$29,549
Praluent PenAlirocumab35$23,242
Dofetilide152$20,084
Ranolazine ErRanolazine141$13,056
NexlizetBempedoic Acid/Ezetimibe17$12,657
Icosapent Ethyl40$8,790
Rosuvastatin Calcium556$6,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$534$698,942690 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$48$380,63312 claims
NovartisEntresto$1,333$244,244218 claims
Johnson & JohnsonXarelto$422$132,178142 claims
AstraZenecaFarxiga$923$55,44563 claims
Sanofi-aventis U.S. LLCMultaq$403$48,00537 claims
Boehringer IngelheimJardiance$516$29,54930 claims
Esperion Therapeutics, Inc.Nexlizet$684$12,65717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →